论文部分内容阅读
最近举行的美国临床肿瘤学会ASCO会议再次提出了靶向治疗 ,并提出了联合用药和应用多靶向药物的概念 ,这会比前几代药物更有效 ,产生更高的效益。会议重点介绍了辉瑞和拜耳公司生产的新的血管生成抑制剂 ,用于治疗肾癌 ;Genentech/Roche公司的一种表皮生长因子受体 (EGFR)靶向
The recently held ASCO meeting of the American Society of Clinical Oncology has again proposed targeted therapies and proposed the concept of combination therapy and the use of multi-targeted drugs, which would be more effective and cost-effective than previous generations of drugs. The conference focused on new angiogenesis inhibitors produced by Pfizer and Bayer for the treatment of kidney cancer; a Genentech / Roche company that targets the epidermal growth factor receptor (EGFR)